Kyowa Kirin Co., Ltd. (KYKOF)
- Previous Close
17.63 - Open
17.63 - Bid --
- Ask --
- Day's Range
17.63 - 17.63 - 52 Week Range
15.78 - 22.67 - Volume
100 - Avg. Volume
465 - Market Cap (intraday)
9.478B - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
25.55 - EPS (TTM)
0.69 - Earnings Date --
- Forward Dividend & Yield 0.39 (2.23%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
--
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
www.kyowakirin.com5,974
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: KYKOF
Performance Overview: KYKOF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KYKOF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KYKOF
Valuation Measures
Market Cap
9.09B
Enterprise Value
6.62B
Trailing P/E
25.41
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.50
Price/Book (mrq)
1.81
Enterprise Value/Revenue
0.02
Enterprise Value/EBITDA
0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
18.36%
Return on Assets (ttm)
6.09%
Return on Equity (ttm)
10.15%
Revenue (ttm)
442.23B
Net Income Avi to Common (ttm)
81.19B
Diluted EPS (ttm)
0.69
Balance Sheet and Cash Flow
Total Cash (mrq)
405.01B
Total Debt/Equity (mrq)
2.31%
Levered Free Cash Flow (ttm)
69.29B
Research Analysis: KYKOF
Company Insights: KYKOF
KYKOF does not have Company Insights